BERKELEY, Calif., May 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation announced that Dino Dina, MD, President and CEO, will present an overview of the company at the Friedman Billings Ramsey Growth Investor conference, May 31, 2006 at 12:45 p.m. Eastern, in New York. The webcast presentation may be accessed by visiting http://www.wsw.com/webcast/fbr15/dvax/ .
The presentation may also be accessed by visiting the Dynavax website at http://www.Dynavax.com under the Investors section where it will also be archived for 60 days following the presentation.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR-9 agonist-based products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax’s pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic, for which a major safety and efficacy trial (DARTT) is currently underway, and that is in a supportive clinical trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine that is currently in a Phase 3 clinical trial; SUPERVAX, a hepatitis B vaccine; a cancer therapy currently in a Phase 2 clinical trial in non-Hodgkins lymphoma; an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial; and preclinical programs in hepatitis B and hepatitis C therapy.
Dynavax Technologies Corporation
CONTACT: Jane M. Green, PhD, Vice President, Corporate Communications, ofDynavax Technologies Corporation, +1-510-665-4630 or jgreen@dvax.com
Web site: http://www.dynavax.com//
